| Announcement | Date |
|---|---|
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDAOn 5/15/2018, Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa), for all indications of the reference product. Please see the full press release via the link below for further details. |
May 15, 2018 |
Ibrance (palbociclib) Recommended Dose Modifications for Adverse ReactionsA new dose modification interactive tool for Ibrance is now available on Ibrance Medication Page. |
May 3, 2018 |
Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years. |
April 23, 2018 |
Chat Online service is currently unavailableChat Online service is currently unavailable. If you have a medical question regarding a Pfizer prescription product, please click here to return to the website to search our document database or submit your question via the web form here. Alternatively, you may contact us by telephone at 1-800-438-1985, 8am-7pm ET Monday-Friday. |
April 13, 2018 |
Limited Release of Quillivant XR |
March 23, 2018 |
Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers |
March 23, 2018 |
Transparency on Every Level - Supply Shortage Recovery Plan and Plans to Mitigate Shortages in the FuturePfizer deeply understands the impact of shortages of some products in our portfolio on customers and their patients, and is doing everything possible to resolve current shortages. We have developed an in-depth video series to provide our customers with open and transparent communication throughout our recovery efforts. Watch below to hear from individuals at every level of the organization as they discuss progress against our supply shortage recovery plan and plans to mitigate shortages in the future. |
March 19, 2018 |
Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis |
March 13, 2018 |
US Food and Drug Administration Extends Action Date for Xeljanz (Tofacitinib) Supplemental New Drug Application in Ulcerative Colitis by Three Months |
December 13, 2017 |
Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG is the first therapy with an indication that includes pediatric AML. It is also the only AML therapy that targets CD33, an antigen expressed on AML cells in up to 90% of patients. |
September 12, 2017 |
Overview of Quillivant XR (video presentation) |
February 22, 2017 |
Overview of QuilliChew ER (video presentation) |
February 22, 2017 |